1. Arcamone, F., Doxorubicin antibiotics: Medicinal Chemistry, A Series of Mono-graphs. G. De Stevens (Ed.). Academic Press, New York, pp. 17 (1982).
2. Azoulay, M., Florent, J. -C., Monneret, C., Gesson, J. P., Jacquesy, J. C., Tillequin, F., Koch, M., Bosslet, K., Czech, J., and Hoffman, D., Prodrugs of anthracycline antibiotics suited for tumor-specific activation.Anti Cancer Drug Des., 10, 441–450 (1995).
3. Bagshawe, K. D., Antibody directed enzymes revive anti-cancer prodrugs concept.Br. J. Cancer., 56, 531–532 (1987).
4. Bagshawe, K. D., Springer, C. J., Searle, F., Antoniw, P., Sharma, S. K., Melton, R. G., and Sherwood, R. F., A cytotoxic agent can be generated selectively at cancer site.Br. J. Cancer, 58, 700–703 (1988).
5. Bagshawe, K. D., Sharma, S. K., Springer, C. J., Antoniw, P., Boden, J. A., Rogers, G.T, Burke, P. J., Melton, R. G., and Sherwood, R. F., Antibody directed enzyme prodrug therapy (ADEPT): clinical report.Dis. Markers, 9, 233–238 (1991).